283,181 followers
@Eddie_Cliff An RCT with bad primary endpoint also dangerous Here is what they are up to https://t.co/EQF8toaVJ0
283,181 followers
Here was that summary along with pitfalls https://t.co/sn497wPXSM
3,744 followers
RT @VPrasadMDMPH: Our new paper is out today in Nature Reviews Clinical Oncology. The FDA is continuing the vein of aducanumab... lower…
114 followers
RT @NatRevClinOncol: In a new Comment now online, Mark Lythgoe and @VPrasadMDMPH discuss the FDA’s latest move to expand eligibility for on…
2,643 followers
RT @VPrasadMDMPH: Our new paper is out today in Nature Reviews Clinical Oncology. The FDA is continuing the vein of aducanumab... lower…
3,285 followers
RT @NatRevClinOncol: In a new Comment now online, Mark Lythgoe and @VPrasadMDMPH discuss the FDA’s latest move to expand eligibility for on…
120 followers
RT @VPrasadMDMPH: Our new paper is out today in Nature Reviews Clinical Oncology. The FDA is continuing the vein of aducanumab... lower…
2,305 followers
RT @vkprasadlab: 33. With @mlythoe we look at the FDA's latest move to expand eligibility. The way they are going about it means many pts…
1,377 followers
RT @VPrasadMDMPH: Our new paper is out today in Nature Reviews Clinical Oncology. The FDA is continuing the vein of aducanumab... lower…
505 followers
RT @vkprasadlab: 33. With @mlythoe we look at the FDA's latest move to expand eligibility. The way they are going about it means many pts…
6 followers
RT @vkprasadlab: 33. With @mlythoe we look at the FDA's latest move to expand eligibility. The way they are going about it means many pts…
26 followers
RT @mlythoe: Happy to share new commentary in @NatRevClinOncol with excellent @VPrasadMDMPH about new draft @FDAOncology guidance with impl…
591 followers
RT @VPrasadMDMPH: Our new paper is out today in Nature Reviews Clinical Oncology. The FDA is continuing the vein of aducanumab... lower…
591 followers
RT @vkprasadlab: 33. With @mlythoe we look at the FDA's latest move to expand eligibility. The way they are going about it means many pts…
4,083 followers
RT @VPrasadMDMPH: Our new paper is out today in Nature Reviews Clinical Oncology. The FDA is continuing the vein of aducanumab... lower…
276 followers
RT @VPrasadMDMPH: Our new paper is out today in Nature Reviews Clinical Oncology. The FDA is continuing the vein of aducanumab... lower…
942 followers
RT @VPrasadMDMPH: Our new paper is out today in Nature Reviews Clinical Oncology. The FDA is continuing the vein of aducanumab... lower…
283,181 followers
Our new paper is out today in Nature Reviews Clinical Oncology. The FDA is continuing the vein of aducanumab... lower standards and more profits.... Follow @vkprasadlab for updates on our academic work (The last refuge of #zerocovid)
2,643 followers
33. With @mlythoe we look at the FDA's latest move to expand eligibility. The way they are going about it means many pts may forgo proven treatments. A double edged sword https://t.co/2iPtZwaeqS https://t.co/vcHXcQFvq4
82 followers
RT @NatRevClinOncol: In a new Comment now online, Mark Lythgoe and @VPrasadMDMPH discuss the FDA’s latest move to expand eligibility for on…
82 followers
RT @VPrasadMDMPH: It was awesome to work with @mlythoe, UK oncologist on this So many things so sensible in the UK
82 followers
RT @mlythoe: Happy to share new commentary in @NatRevClinOncol with excellent @VPrasadMDMPH about new draft @FDAOncology guidance with impl…
283,181 followers
RT @mlythoe: Happy to share new commentary in @NatRevClinOncol with excellent @VPrasadMDMPH about new draft @FDAOncology guidance with impl…
505 followers
Happy to share new commentary in @NatRevClinOncol with excellent @VPrasadMDMPH about new draft @FDAOncology guidance with implications for global #oncology #clinicaltrials https://t.co/9DCRRF2L08
221 followers
RT @VPrasadMDMPH: It was awesome to work with @mlythoe, UK oncologist on this So many things so sensible in the UK
505 followers
RT @VPrasadMDMPH: It was awesome to work with @mlythoe, UK oncologist on this So many things so sensible in the UK
283,181 followers
It was awesome to work with @mlythoe, UK oncologist on this So many things so sensible in the UK
505 followers
RT @NatRevClinOncol: In a new Comment now online, Mark Lythgoe and @VPrasadMDMPH discuss the FDA’s latest move to expand eligibility for on…
39,972 followers
In a new Comment now online, Mark Lythgoe and @VPrasadMDMPH discuss the FDA’s latest move to expand eligibility for oncology trials. Is it a double-edged sword? @NatResCancer https://t.co/gecA2EffYX https://t.co/Qtcnn168tm